Pergamum implements offset share issue worth SEK 120m
(Thomson Reuters ONE) -
STOCKHOLM - May 12, 2011. Pergamum AB, Karolinska Development's portfolio
company within wound- and skin infections, has conducted an offset share issue,
amounting to a total value of SEK 119.6m (EUR 13.3m). Of the total amount, SEK
77.6m (EUR 8.7m) comes from Karolinska Development, thereby increasing its
ownership from 60 to 61 percent.
Pergamum was founded in 2009 in order to create a strong company in the
development of new, effective treatments for wound- and skin infections. The
company currently has two Phase II programs, DPK-060 in skin- and soft tissue
infections and PXL01 for the prevention of post-surgical adhesions. Another
project, LL37 in wound healing, is scheduled to enter clinical development this
year.
Torbjörn Bjerke, CEO, Karolinska Development:
"Through the completion of this offset issue, we demonstrate our increased
commitment in a company that we believe will be able to develop innovative
products in areas of high unmet medical needs and with great commercial
potential."
Jonas Ekblom, CEO, Pergamum:
"We are proud that Karolinska Development chooses to raise its holdings in
Pergamum and we look forward to a long-term working relation with our
shareholders to further develop our innovative treatment concepts."
In this transaction, debts totaling SEK 119.6m (EUR 13.3m) are offset against
shares in Pergamum AB. A part of the total amount, equivalent to SEK 77.6m (EUR
8.7m) stems from Karolinska Development which increases its holdings from 60 to
61 percent in the transaction.
For further information, please contact:
Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0) 727 44 41 23, e-mail: torbjorn.bjerke(at)karolinskadevelopment.com
Jonas Ekblom, CEO, Pergamum AB
Phone: +46-8-524 89 100, e-mail: jonas.ekblom(at)pergmum.com
TO THE EDITORS
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class research into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP these to
the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out licensing of
products. This will result in upfront payments, milestone payments and
royalties.
An exclusive deal flow agreement with Karolinska Institutet Innovations AB,
along with other cooperation agreements with leading Nordic universities,
delivers a continuous flow of innovations.
Karolinska Development's flexible exit strategy enables projects to be exited at
whichever stage of development offers the greatest return on investment, usually
after Phase II clinical trials have indicated the desired pharmaceutical effect
on patients - this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from
concept development to Phase II clinical trials, twelve projects are in clinical
trials with six in Phase II. The portfolio is particularly strong in the areas
of cancer, dermatology, inflammation, cardiovascular disease, women's health and
diseases that affect the central nervous system.
www.karolinskadevelopment.com
About Pergamum
Pergamum is a biopharmaceutical company, with headquarters in Stockholm, that is
specialized in the development of innovative drugs for the treatment of wounds
and skin infections. The company is currently conducting a number of research
and development programs, several being at the clinical stage.www.pergamum.com
Read Press Release as PDF:
http://hugin.info/143071/R/1514936/451102.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1514936]
Unternehmensinformation / Kurzprofil:
Datum: 12.05.2011 - 09:00 Uhr
Sprache: Deutsch
News-ID 54580
Anzahl Zeichen: 4732
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pergamum implements offset share issue worth SEK 120m"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
